Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207155 · ClinicalTrials.gov registry record · Phase 1
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT00207155 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 110 participants.
The verdict
NCT00207155, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
Interventions
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207155
The ClinicalTrials.gov registry entry for NCT00207155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT00207155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00207155 about?
NCT00207155 is a clinical study titled "An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer". The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
What is the current status of trial NCT00207155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2003-12. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00207155?
The interventions under investigation include: Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00207155?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.